Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects

Giorgia Teresa Maniscalco a,*, Anne Lise Ferrara c,*, Antonietta Liotti c, Valentino Manzo a, Maria Elena Di Battista a, b, Simona Salvatore a, b, Daniela Graziano a, Assunta Viola f, Gerardino Amato g, Ornella Moreggia b, Daniele Di Giulio Cesare b, Gennaro Alfieri a, Walter Di Iorio a, Gennaro Della Rocca a, Vincenzo Andreone a,*, Veronica De Rosa c.

a Neurological Clinic and Stroke Unit, “A. Cardarelli” Hospital, Via A. Cardarelli 9, Naples 80131, Italy
b Multiple Sclerosis Center, “A. Cardarelli” Hospital, Via A. Cardarelli 9, Naples 80131, Italy
c Institute of Experimental Endocrinology and Oncology (IEOS-CNR), Via S. Pansini 5, Naples 80131, Italy
d Department of Translational Medical Science and Center for Basic and Clinical Immunology Research (CISI), University of Naples “Federico II”, Via S. Pansini 5, Naples 80131, Italy
*e-mail addresses: gtmaniscalco@libero.it (G.T. Maniscalco), tonialiotti@virgilio.it (A. Liotti), valentino.manzo@aocardarelli.it (V. Manzo), mariaelena.dibattista@aocardarelli.it (M.E. Di Battista), simona.salvatore@aocardarelli.it (S. Salvatore), dania.graziano@aocardarelli.it (D. Graziano), assunta.viola@aocardarelli.it (A. Viola), gerardino.amato@aocardarelli.it (G. Amato), daniel.dgc@alice.com (D. Di Giulio Cesare), gennaro.alfieri@aocardarelli.it (G. Alfieri), walter.diorio@aocardarelli.it (W. Di Iorio), gennaro.dellarocca@aocardarelli.it (G. Della Rocca), vincenzo.andreone@aocardarelli.it (V. Andreone), veronica.de_rosa@cnr.it (V. De Rosa).

**Corresponding author.

**GTM and ALF contributed equally to this work.

**VA and VDR contributed equally as senior authors to this work.

Results: When compared with SARS-CoV-2 IgG levels at T2 in HC, we observed comparable levels in interferon-β 1α, dimethyl fumarate-, teriflunomide- and natalizumab-treated MS subjects, but an impaired humoral response in MS subjects undergoing glatiramer acetate-, cladribine-, fingolimod- and ocrelizumab-treatments. Moreover, comparison between SARS-CoV-2 IgG Spike titre at T1 and T2 revealed a faster decline of the humoral response in patients undergoing dimethyl fumarate-, interferon-β 1α- and glatiramer acetate-therapies, while those receiving teriflunomide and natalizumab showed higher persistence compared to healthy controls.

Conclusion: The prominent decline in humoral response in MS subjects undergoing dimethyl fumarate-, interferon-β 1α- and glatiramer acetate-therapies should be considered when formulating booster regimens as these subjects would benefit of early booster vaccinations.

**Abbreviations: CLAD, Cladribine; COVID-19, Coronavirus disease 2019; DMF, Dimethyl fumarate; DMTs, Disease modifying therapies; EDSS, Expanded disability status scale; FTY, Fingolimod; GA, Glatiramer acetate; HC, Healthy controls; IgG, Immunoglobulin G; INF, Interferon-β 1α; IQR, Interquartile range; MS, Multiple sclerosis; NAT, Natalizumab; OCRE, Ocrelizumab; PPMS, Primary progressive multiple sclerosis; RRMS, Relapsing remitting multiple sclerosis; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; SPMS, Secondary progressive multiple sclerosis; TERI, Teriflunomide.

* Corresponding author.
1. Introduction

Vaccination against the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become a global priority as coronavirus disease 2019 (COVID-19) presents a severe or life-threatening disease course up to 5–10% of cases (Gavriatopoulou et al., 2020). Among all the available vaccines, BNT162b2 mRNA has been shown to induce high levels of the anti-SARS-CoV-2 Spike-receptor binding domain (RBD) IgG neutralizing antibodies (NAbs) that strongly correlate with clinical immune protection from COVID-19 in healthy subjects (Maniscalco et al., 2021). In light of the current discussion regarding SARS-CoV-2 booster vaccinations, several studies have evaluated the duration of anti-SARS-CoV-2 immune protection in healthy individuals (A Achiron et al., 2021; Andrews et al., 2022); however clinical data suggest an attenuated short-term humoral response to SARS-CoV-2 vaccines in patients with MS receiving DMTs (Tortorella et al., 2021; Capuano et al., 2022).

Here we present a prospective study aimed at assessing the six-months persistence of the humoral response in a monocentric cohort of MS patients treated with eight different DMTs compared with healthy subjects, all receiving BNT162b2 mRNA vaccine and without previous SARS-CoV-2 infection.

2. Materials and methods

2.1. Subjects and study design

This is a prospective monocentric study to evaluate the kinetics of SARS-CoV-2 IgG Spike titre 5–6 months after the second dose of BNT162b2 vaccine in MS subjects undergoing vaccination at the Multiple Sclerosis centre of the Cardarelli Hospital (Naples, Italy) from March to November 2021. All human subjects were enrolled after obtaining informed consent. The study was approved by the Institutional Review Board of the Cardarelli Hospital. We enrolled 96 MS and 21 healthy controls receiving the two doses of BNT162b2 vaccine according to the recommendations of Italian Authority of Health, all without previous SARS-CoV-2 infection. MS subjects were vaccinated according to specific timing; more in detail, MS subjects treated with IFN, GA, TERI, DMF, FTY and NAT were vaccinated without any interruption of immunomodulatory treatment, while CLAD- and OCRE-treated MS subjects were vaccinated at least 1 or 3 months respectively after the last therapeutic administration, according to the recommendations of Italian Authority of Health. Blood samples were collected at 9:00 AM into heparinized Vacutainers (BD Biosciences) and processed within the following 4 h. Demographic and clinical characteristics of the study cohort are shown in Table 1. Inclusion criteria were patients aged between 18 and 65 years, diagnosed with multiple sclerosis treated with DMTs for at least 6 months. Exclusion criteria were previous SARS-CoV-2 infection (antibody screening), any relapse and/or steroid use in the last 30 days before enrolment. Healthy subjects were matched for age and sex and had no history of inflammation, endocrine or autoimmune disease. The ethnic distribution among the groups was comparable, with all participants being Caucasian.

2.2. SARS-CoV-2 IgG spike detection

Quantitative determination of antibodies to the SARS-CoV-2 Spike protein was carried out by Roche Elecsys® Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). The assay was performed using a recombinant protein representing the RBD of the S antigen leading to a double-antigen sandwich assay complex which favors detection of high affinity antibodies against SARS-CoV-2 (range between 0.4 to 250 U/mL), resulting in a sensitivity of 98.8% (95% CI: 98.1 – 99.3%).

2.3. Ethics (standard protocol approvals, registrations and patient consents)

The study was conducted according the Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. Investigators obtained ethic committee approval for the study protocol and amendments by the local Ethic Committee of A.O.R.N. A. Cardarelli/Santobono-Pausilipon (protocol number 2821). All subjects gave written informed consent to participate to the study.

2.4. Statistical analysis

Descriptive analyses were presented as mean (± standard error of the mean), median and interquartile range (IQR). Categorical variables were described as frequency and percentage. A Shapiro-wilk test was performed to assess the normal distribution of data. In case of not-normal distribution appropriate non-parametric tests were performed (Wilcoxon test). The fold persistence of SARS-CoV-2 Spike IgG titre was calculated as the percentage ratio between IgG titre at T2 and T1, relative to HC (100%). F-value less of 0.05 indicated significance. A multilinear regression model was used to compare the antibody levels across subjects treated with different DMTs after adjusting for age, sex, EDSS levels, disease and DMT duration and antibody levels in the pre-booster samples. Data analyses were performed using Graphpad Prism (version 8).

3. Results

3.1. Study cohort

Data were collected from March to November 2021. In this table clinical and demographic characteristics of the study cohort.

| Table 1 Clinical and demographic characteristics of the study cohort. |  |
|---|---|
| **MS patients (N = 96)** | **Healthy Controls (N = 21)** |
| **Gender, n (%)** |  |
| Female | 57 (59.4) |
| Male | 39 (40.6) |
| **Age, years** |  |
| Mean age (±SD) | 40.7 (±10.5) |
| IQR (25–75) | 14.5 |
| EDSS, mean (range) | 1.9 (0–6.5) |
| DMTs duration, mean (months ± SD) | 50.2 (±41.5) |
| **MS type, n (%)** |  |
| RRMS | 91 (94.8) |
| PPMS | 1 (1.04) |
| SPMS | 4 (4.2) |
| **DMTs, n (%)** |  |
| Interferon-β 1a | 19 (19.8) |
| Natalizumab | 14 (14.6) |
| Dimethyl fumarate | 14 (14.6) |
| Ocrelizumab | 13 (13.5) |
| Fingolimod | 13 (13.5) |
| Teriflunomide | 8 (8.3) |
| Cladribine | 8 (8.3) |
| Gilaniem acetate | 7 (7.4) |

**DMTs**: Disease modifying therapy; **EDSS**: Expanded disability status scale; **IQR**: Interquartile range; **MS**: Multiple sclerosis; **PPMS**: Primary progressive multiple sclerosis; **RRMS**: Relapsing remitting multiple sclerosis; **SPMS**: Secondary progressive multiple sclerosis.
prospective monocentric study, we excluded subjects previously infected with SARS-CoV-2, through the measurement of nucleocapsid-specific antibodies. After assessment, 96 MS patients and 21 HC were evaluated for anti-Spike IgG levels, 21 days (T1) and 5–6 months (T2) after the second SARS-CoV-2 BNT162b2 mRNA vaccine dose. The demographic and clinical characteristics are reported in Table 1. In the MS group, 57 were females (59.4%) and 39 male (40.6%) and the mean age was 40.7 ± 10.5 (mean ± SD) years. In the control group (HC), 11 subjects were females (52.4%) and 10 males (47.6%), with a mean age of 48.3 ± 10.8 (mean ± SD) years. In the MS cohort, 91 had relapsing-remitting (RR) (94.8%), 1 primary-progressive (PP) (1.04%) and 4 secondary-progressive (SP) (4.2%) MS. Different types of disease-modifying therapies (DMTs) were: interferon-β1a (IFN) (n = 19; 19.8%), natalizumab (NAT) (n = 14; 14.6%), dimethyl fumarate (DMF) (n = 14; 14.6%), ocrelizumab (OCRE) (n = 13; 13.5%), fingolimod (FTY) (n = 13; 13.5%), teriflunomide (TERI) (n = 8; 8.3%), cladribine (CLAD) (n = 8; 8.3%), and glatiramer acetate (GA) (n = 7; 7.4%).

3.2. SARS-CoV-2-specific humoral response declines differently in MS subjects undergoing distinct disease-modifying therapies (DMTs)

We previously reported that IFN-treated MS subjects showed a significant increase of anti-Spike IgG levels compared to HC, while humoral response was profoundly affected in MS subjects undergoing CLAD, FTY and OCRE, 21 days after the second BNT162b2 mRNA vaccine dose (Sormani et al., 2021). We aimed at evaluating the persistence of the SARS-CoV-2 IgG titre 5–6 months after the second vaccine dose (T2), in our monocentric cohort of MS subjects undergoing different DMTs, respect to age- and sex-matched HC. We found that SARS-CoV-2 IgG levels in MS subjects under treatment with IFN (median 566.6 (IQR: 427.5–1182) U/mL), DMF (median 694.6 (IQR: 438.3–1103) U/mL) TERI (median 507.8 (IQR: 278.7–1514) U/mL) and NAT (median 456.4 (IQR: 198.6–1156) U/mL) were comparable to HC (median 533.8 (IQR: 366.4–1008) U/mL) (Fig. 1 A and Table 2). On the contrary, humoral response at T2 was reduced in GA- (median 232.9 (IQR: 167.5–440.4) U/mL), CLAD- (median 246.5 (IQR: 145.3–363.3) U/mL) and FTY- (median 70.71 (IQR: 13.22–157.3) U/mL) and almost undetectable in OCRE- (median 0.4 (IQR: 0.4–4.3) U/mL) treated MS subjects (Fig. 1 A and Table 2). Follow-up of our monocentric cohort at 6 months revealed

Fig. 1. (A) SARS-CoV-2 IgG Spike titre (median with IQR) in MS subjects treated with different DMTs, 5–6 months after the second vaccine dose (T2) compared to healthy controls (HC). Wilcoxon two-tailed test vs HC subjects was performed and a p-value less than 0.05 was considered statistically significant. * p<0.05; **p<0.01; ****p<0.0001. (B) SARS-CoV-2 IgG Spike titre kinetics (mean ± SEM) of MS subjects treated with different DMTs at 21 days (T1) and 5–6 months (T2) after the second vaccine dose, compared to HC. Wilcoxon two-tailed test was performed to compare T1 and T2 levels and a p-value less than 0.05 was considered statistically significant. * p<0.05; **p<0.01; ***p<0.005; ****p<0.0001. (C) Fold percentage of SARS-CoV-2 IgG Spike titre persistence (mean ± SEM) of MS subjects treated with different DMTs at T2, relative to HC (100%). Wilcoxon two-tailed test vs HC subjects was performed and a p-value less than 0.05 was considered statistically significant. * p<0.05; ****p<0.0001.
a significant drop in anti-Spike IgG titre compared to the relative T1 IgG values in HC (median 533.8 (IQR: 366.4 – 1008) vs 1087 (IQR:940.3 – 1542) U/mL), IFN- (median 566.6 (IQR: 427.5 – 1182) vs 1909 (IQR: 1073 – 2758) U/mL), DMF- (median 694.6 (IQR: 438.3 – 1103) vs 1587 (IQR:767.7 – 3472) U/mL), NAT- (median 456.4 (IQR: 198.6 – 1156) vs 735.1 (IQR: 351.3 – 2151) U/mL) and GA- (median 232.9 (IQR: 167.5 – 440.4) vs 466.5 (IQR: 417.7 – 3034) U/mL) treated MS patients (Table 2). The reduction was not significant in TERI-, CLAD- and OCORE-treated MS groups, while subjects under FTY showed a slight - albeit irrelevant - increase of anti-Spike IgG at T2 compared to their T1 levels (Fig. 1B e Table 2). Finally, in those groups of DMT-treated MS subjects having shown a significant antibody production after the second SARS-CoV-2 BNT162b2 mRNA vaccine dose, we evaluated the persistence of the humoral response at 6 months, expressed as the percentage ratio between IgG titre at T2 and T1, relative to HC (Fig. 1C). When compared to healthy controls, we observed a faster decline of anti-Spike IgG levels in patients undergoing DMF- (75.7 ± 11.5%), IFN- (62.4 ± 6.7%) and GA- (54.3 ± 11.3%) therapies, while those receiving TERI and NAT showed an increased persistence (130.9 ± 34.4% and 127.2 ± 32.6%, respectively), still not reaching the statistical significance (Fig. 1C). We performed linear regression analyses to rule out that individual factors or clinical variables (age, sex, EDSS, DMT duration, time to last therapeutic administration) could affect the SARS-CoV-2 vaccine humoral response at T2, but we did not find any significant correlation between these parameters and IgG-Spike titre in the different DMT groups (data not shown). Our data highlight how DMTs could differentially promote the persistence of protective SARS-CoV-2 humoral response in MS subjects.

4. Discussion

Our study shows that antibody responses to SARS-CoV-2 BNT162b2 mRNA vaccine are broadly distributed and declined substantially in most individuals over time. Antibodies are key immune effectors that confer protection against pathogens (Chen et al., 2020). The longevity of the antibody response to SARS-CoV-2 vaccine in multiple sclerosis (MS) subjects are still not well defined. In this context, decisions regarding initiation or continuation of specific disease modifying therapy (DMT) have to consider the potential relevance to the pandemic. Understanding the possible distinct effects of each therapeutic agent on the immune response to the vaccine is essential during this special time.

In this monocentric study, we charted longitudinal anti-Spike specific IgG antibody response to SARS-CoV-2 BNT162b2 mRNA vaccine in MS subjects undergoing eight different DMTs, compared to healthy controls (HC). 96 MS subjects followed longitudinally from day 21 (T1) to 5–6 months (T2) after the second SARS-CoV-2 BNT162b2 vaccine dose showed marked heterogeneity in antibody duration dynamics. Anti-Spike IgG decayed substantially in most individuals, whereas distinct groups had stable or increasing antibody levels in the same time frame (T2), despite the initial antibody magnitudes at T1. More in detail, anti-Spike IgG levels at T2 were comparable among IFN-, DMF-, TERI- and NAT-treated MS subjects and reflect those of HC. Conversely, antibody levels were significantly reduced in MS subjects under GA-, CLAD-, FTY-treatments and almost absent in OCORE-treated MS groups. Vaccination of cladribine-treated subjects occurred at least one month after the last therapy, in line with the Italian Authority of Health recommendations (Centonze et al., 2021); as these subjects have reduced anti-Spike IgG levels, this aspect should be considered in the selection of the booster time administration.

However, based on their anti-Spike IgG levels at T1, we evaluated the antibody persistence in those DMT-groups exhibiting an adequate humoral response after vaccination. We observed that, when compared to HC, TERI- and NAT-treated MS subjects showed an increased persistence of anti-Spike specific IgG antibody response to SARS-CoV-2 BNT162b2 mRNA vaccine after 5–6 months, while DMF-, IFN- and GA-therapies affected the retention of the humoral response over time. An important implication of our data is the possible existence of an efficient SARS-CoV-2 vaccine “holder” phenotype, defined as individuals who experience relatively sustained anti-SARS-CoV-2 IgG production. This seems to be the case of MS under teriflunomide, which selectively inhibits dihydro-orotate dehydrogenase (DHODH), an important mitochondrial enzyme in the de novo pyrimidine synthesis pathway. The downstream effect is the reduced proliferation of rapidly dividing cells, including activated T and B lymphocytes. It has been reported that TERI-treated MS patients developed effective immunity to seasonal influenza after vaccination. In addition, there is emerging evidence suggesting a direct antiviral effect for teriflunomide and other DHODH inhibitors against a range of viruses such as Thieiler’s, respiratory syncytial, Ebola, cyto-megalovirus, Epstein–Barr, and picornaviruses (Maghzi et al., 2020). Moreover, our data are in line with the successful development of anti-SARS-CoV-2 antibodies described in patients under teriflunomide after COVID-19 infection (Bollo et al., 2020). Regarding natalizumab, it acts as an antagonist to alpha-4 integrin on leukocyte surface, blocking their interaction with vascular cell adhesion molecules and preventing leukocyte migration to the CNS. Data from influenza vaccine studies strongly support its treatment under the COVID-19 pandemic; however, some concerns have been raised regarding the potential increase of viral shedding due to the reduction of lymphocyte trafficking in the lungs (Aguirre et al., 2020). Since our data unveiled a slight increase in both T1 and T2 anti-Spike IgG levels compared to HC and a good humoral persistence, this could suggest a delayed booster timing for NAT-treated MS subjects. The same holds true also for FTY-treated subjects occurred at least one month after the last therapy, in line with the Italian Authority of Health recommendations (Centonze et al., 2021); as these subjects have reduced anti-Spike IgG levels, this aspect should be considered in the selection of the booster regimen in MS subjects.

5. Data access, responsibility, and analysis

The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author contributions

G.T. Maniscalco, A.L. Ferrara, V. De Rosa: Conceptualization; A.L. Ferrara, A. Liotti, D. Di Giulio Cesare, O. Moreggia: Data curation; A.L. Ferrara, A. Liotti, D. Di Giulio Cesare: Formal analysis; G.T. Maniscalco, V. De Rosa: Investigation; G.T. Maniscalco, V. De Rosa:
Maghzi, A.H., Houtchens, M.K., Preziosa, P., Ionete, C., Beretich, B.D., Stankiewicz, J.M., Tauhid, S., Cabot, A., Berrisomorales, I., Schwartz, T.H.W., Sloane, J.A., Freedman, M.S., Filippi, M., Weiner, H.L., Bakshi, R., 2020. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J. Neurol. 267 (10), 2790–2796. https://doi.org/10.1007/s00415-020-09944-8.

Bollo, L., Guerra, T., Bavaro, D.F., Monno, L., Saracino, A., Angarano, G., Paolicelli, D., Trojano, M., Iaffaldano, P., 2020. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J. Neurol. Sci. 416, 117011 https://doi.org/10.1016/j.jns.2020.117011.

Aguirre, C., Meca-Lallana, V., Barrios-Blandino, A., Del Rio, B., Vivancos, J., 2020. Covid-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role? Mult. Scler. Relat. Disord. 44, 102250 https://doi.org/10.1016/j.msard.2020.102250;

Achiron, A., Mandel, M., Dreyer-Alster, S., Harari, G., Dolev, M., Menascu, S., Magalashvili, D., Flechter, S., Givon, U., Gaber, D., Sonis, P., Zilku-Falb, R., Gurevich, M., 2021b. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study. J. Neuroimmunol. 361, 577746 https://doi.org/10.1016/j.jneuroim.2021.577746.